title: Factors affecting long-term compliance of osteoporotic patients with bisphosphonate treatment and QOL assessment in actual practice: alendronate and risedronate.
abstract: The aim of our study was to examine compliance with a daily dose of 5 mg alendronate (ALN) and 2.5 mg risedronate (RDN) in actual practice, and to determine the causes of noncompliance through a questionnaire. In addition, we studied the quality of life (QOL) of patients through another disease-related questionnaire. The overall compliance rate remained at approximately 40% one year after the initial dose. The rates did not differ significantly between the ALN group (783 patients) and the RDN group (491 patients). The compliances in the female group and the rheumatism group were better than in the male group and the nonrheumatism group. From the questionnaire, 36% of noncompliant patients showed adverse effects (AEs), and the other noncompliant patients stopped the medication in spite of having no AEs. A logistic regression analysis of factors that might have affected long-term compliance included AEs, an understanding of the disease, the method of ingestion, visiting medical facilities, the shape of the tablet, the cost of the drug, and the explanation of the doctor or pharmacist. This analysis showed that noncompliance occurred mainly due to AEs, the inconvenience of visiting a medical facility, unusual methods of ingestion, and a poor understanding of the disease. According to the results of the questionnaire for QOL assessment, the patients who continued the medication for more than 1 year had improved scores for pain in both the ALN and RDN groups. Osteoporotic treatment needs long-term patient compliance. To improve compliance, it is very important that doctors and pharmacists ensure that patients understand the purpose of this therapy.
authors: Maruzen Pharmacy, 3-3-23-104 Nishimikuni, Yodogawa-ku, Osaka 532-0006, Japan. kama89314@yahoo.co.jp
authors: Masayuki
authors: M
authors: Kamatari
authors: Shiro
authors: S
authors: Koto
authors: Nobuhiro
authors: N
authors: Ozawa
authors: Chie
authors: C
authors: Urao
authors: Yumiko
authors: Y
authors: Suzuki
authors: Eri
authors: E
authors: Akasaka
authors: Kae
authors: K
authors: Yanagimoto
authors: Kazumi
authors: K
authors: Sakota
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D019386:Alendronate / Q000008:administration & dosage / Q000627:therapeutic use; D004164:Diphosphonates / Q000008:administration & dosage / Q000627:therapeutic use*; D012968:Etidronic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D005260:Female; D006801:Humans; D016015:Logistic Models; D008297:Male; D010024:Osteoporosis / Q000188:drug therapy* / Q000473:pathology; D010349:Patient Compliance / Q000706:statistics & numerical data*; D011788:Quality of Life; D000068296:Risedronic Acid; D011795:Surveys and Questionnaires; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D004164:Diphosphonates; D000068296:Risedronic Acid; D012968:Etidronic Acid; D019386:Alendronate
references: Endocr Pract. 2006 Sep-Oct;12(5):522-8
references: 17002926
references: Osteoporos Int. 2003 Dec;14(12):965-8
references: 14504697
references: Arch Intern Med. 2005 Nov 14;165(20):2414-9
references: 16287772
references: Clin Ther. 2002 Nov;24(11):1871-86
references: 12501880
references: J Bone Miner Metab. 2005;23(2):167-73
references: 15750696
references: Nurs Clin North Am. 2001 Sep;36(3):433-40, viii
references: 11532658
references: JAMA. 1999 Aug 18;282(7):637-45
references: 10517716
references: Yonsei Med J. 2003 Dec 30;44(6):961-7
references: 14703602
references: South Med J. 2006 Jun;99(6):570-5
references: 16800411
references: N Engl J Med. 1995 Nov 30;333(22):1437-43
references: 7477143
references: JAMA. 1999 Oct 13;282(14 ):1344-52
references: 10527181
references: J Bone Miner Metab. 2004;22(5):469-78
references: 15316868
references: Pharmacoeconomics. 2002;20(5):289-303
references: 11994039
references: Mayo Clin Proc. 2006 Aug;81(8):1013-22
references: 16901023
references: Osteoporos Int. 2004 Dec;15(12):1003-8
references: 15167989
references: N Engl J Med. 1995 Apr 27;332(17):1125-31
references: 7700285
references: Osteoporos Int. 2006;17(6):922-8
references: 16609824
references: Rheum Dis Clin North Am. 2001 Feb;27(1):163-85, vii
references: 11285993
references: J Pharmacobiodyn. 1981 Nov;4(11):879-85
references: 7328489
references: Osteoporos Int. 2003 Dec;14(12):1007-12
references: 14557854
references: Clin Pharmacol Ther. 1995 Sep;58(3):288-98
references: 7554702
references: Br J Clin Pharmacol. 1999 Oct;48(4):536-42
references: 10583024
references: Osteoporos Int. 2004 Dec;15(12):975-80
references: 15118812
references: Maturitas. 2004 Jul 15;48(3):243-51
references: 15207890
references: Curr Med Res Opin. 2005 Sep;21(9):1453-60
references: 16197664
references: Nat Clin Pract Endocrinol Metab. 2006 Apr;2(4):211-9; quiz following 238
references: 16932286
references: Lancet. 1996 Dec 7;348(9041):1535-41
references: 8950879
references: Gastroenterology. 2000 Sep;119(3):631-8
references: 10982755
references: Isr Med Assoc J. 2003 Dec;5(12):859-62
references: 14689753
references: J Clin Pharm Ther. 1998 Oct;23(5):345-52
references: 9875682
references: Osteoporos Int. 2000;11(1):83-91
references: 10663363
references: JAMA. 1998 Dec 23-30;280(24):2077-82
references: 9875874
references: Osteoporos Int. 2003 May;14(3):259-62
references: 12730745
references: N Engl J Med. 2001 Feb 1;344(5):333-40
references: 11172164
references: Pharm Res. 2001 Feb;18(2):166-70
references: 11405286
references: J Bone Miner Metab. 2004;22(5):462-8
references: 15316867
references: Aust Fam Physician. 2006 Mar;35(3):135-7
references: 16525527
references: Am J Med. 2006 Apr;119(4 Suppl 1):S12-7
references: 16563936
references: Arch Intern Med. 1997 Dec 8-22;157(22):2617-24
references: 9531231
references: Cancer. 2000 Jan 1;88(1):6-14
references: 10618600
references: Endocr Rev. 2002 Aug;23(4):570-8
references: 12202472